Lantheus launches new Definity trial

Lantheus Medical Imaging has launched a multicenter phase IV observational study to further evaluate the safety profile of its Definity ultrasound contrast agent.

The study, called Contrast Echocardiography Registry for Safety Surveillance (CaRES), will examine Definity's safety in patients with suboptimal echocardiograms and provide safety information on the use of ultrasound contrast agents in routine clinical practice, according to the North Billerica, MA-based vendor.

The open-label, nonrandomized registry will be conducted in at least 10 U.S. clinical sites and include at least 1,600 patients, Lantheus said.

Related Reading

Lantheus focuses on cardiac imaging following BMS spinoff, March 27, 2008

Bristol-Myers Squibb unit becomes Lantheus Medical Imaging, March 18, 2008

BMS posts last financials for medical imaging business, February 1, 2008

Avista completes Bristol-Myers Squibb buy, January 10, 2008

Bristol-Myers Squibb finds buyer for imaging unit, December 17, 2007

Copyright © 2008

Page 1 of 509
Next Page